In the post-pandemic era, China’s biopharmaceutical industry has experienced rapid growth. From epidemic prevention supplies to diagnostic technologies and vaccines, China has evolved from being merely a consumer market to a global contributor across the entire life sciences and healthcare sector.

In the future, all segments of the biopharmaceutical industry will witness significant growth. How to establish a long-term strategic presence within China’s domestic industrial ecosystem represents one of the most critical opportunities today. It is evident that the biopharmaceutical industry is characterized by high investment, high risk, high returns, and long R&D cycles. Consequently, cluster-based development has become the most effective path to enhancing the industry’s competitiveness.

In 2017 , with the strong support of Guchuan United, the Chinese medical device unicorn MicroPort settled in the Wujiang Economic and Technological Development Zone to invest in and build a medical sterilization project base.

Today, driven by the anchor effect of MicroPort Medical, over 100 biopharmaceutical and healthcare-related enterprises have established operations across Wujiang. As MicroPort Medical’s project enters the operational and production phase, Wujiang is emerging as a rising star in the medical and healthcare sector.

Multiple Advantages in Place

Wujiang Creates a Fertile Ground for Biopharmaceutical Industry Development

Although Wujiang’s biopharmaceutical industry started early, it has only truly embarked on a path of large-scale industrial development in the past two years. Compared to other industrial clusters that have already matured, Wujiang’s sector remains in its infancy. Nevertheless, the Wujiang biopharmaceutical industry continues to garner significant market anticipation and is a genuine “high-potential stock.”

This confidence stems from the fact that Wujiang itself is a fertile ground with immense potential for the development of the biopharmaceutical industry, possessing numerous core elements that drive the sector forward. A favorable policy environment, unique geographical advantages, a solid industrial foundation, strong innovation capabilities, and a business-friendly environment that values and respects enterprises collectively create fertile ground for the development of the biopharmaceutical industry.

Enterprises remain the core element of industrial clusters and a key driver of their development. For the Wujiang Economic and Technological Development Zone, the arrival of MicroPort Medical—a medical device unicorn—is of immense value, providing a powerful boost to the park’s efforts to attract high-quality enterprises across the entire industrial chain.

Focusing on Industrial Agglomeration

Guchuan United Actively Pursues Targeted Investment Promotion

Founded in 1998 in Zhangjiang Science City, Shanghai, China, MicroPort is an innovative high-end medical device group. Drawing on years of accumulated experience, MicroPort has demonstrated foresight in assessing industry trends and has expanded its operations in step with market dynamics.

In 2017, MicroPort planned to establish a medical sterilization project base in the Yangtze River Delta region. GuChuan United promptly assembled a professional localized service team to thoroughly assess the project’s site requirements. The team conducted research on key indicators—including the industrial environment, preferential policies, available sites, and labor costs—across various regions of the Yangtze River Delta, identifying feasible solutions that closely aligned with the company’s needs.

Subsequently, GuChuan United’s investment promotion team conducted frequent visits and outreach, facilitating efficient communication between the company’s senior management and development zone leaders. They provided full-process accompaniment during site inspections, building a bridge of communication between the government and the enterprise, and ultimately facilitated the project’s establishment in the Wujiang Economic and Technological Development Zone.

The Wujiang Economic and Technological Development Zone’s emphasis on the clustering and development of the biopharmaceutical industry was the fundamental reason why MicroPort Medical chose to locate here. As early as 2014, the Wujiang Development Zone formulated a plan for the development of the biopharmaceutical industry during the 13th Five-Year Plan period. Starting from the need to fill gaps and strengthen the industrial chain, it actively provided various forms of support and guarantees, using the “visible hand” to guide and accelerate industrial development.By 2020, the total output value of Wujiang’s biopharmaceutical industry had reached 4 billion yuan, becoming a crucial link in the region’s industrial backbone.

Leveraging Practical Experience

Facilitating Precise Government-Enterprise Collaboration for Mutual Benefit

The successful establishment of MicroPort Medical in the Wujiang Economic and Technological Development Zone has also laid a solid foundation for the company’s future development. It is reported that MicroPort has over 300 marketed products and collaborates with more than 2,200 hospitals, covering 12 major business clusters including cardiovascular and structural heart disease, cerebrovascular and neuromodulation, and surgical critical care and robotics.

MicroPort’s high-quality development is inseparable from the support of regional advantages. The industrial agglomeration effect of China’s medical device industry is particularly pronounced in the Yangtze River Delta region. The Wujiang Economic Development Zone’s strengths in industrial technology, scientific research talent, and industrial chains provide a strong guarantee for MicroPort’s further development.

Guchuan Lianxing fully recognizes the critical role that targeted investment promotion plays for both governments and enterprises. Moving forward, we will continue to gain a deep understanding of the multi-level needs of governments and enterprises. Leveraging our 12 years of practical experience in the investment promotion industry and a database of over 490,000 project resources, we will bring more high-quality projects to regions suited for their development, creating new momentum for the sustainable growth of regional economies.